Regulation of LRRK2: Identifying vulnerabilities for Parkinson's Disease therapeutics
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative disease, affecting ~10 million people worldwide. One of the most commonly mutated genes in PD codes for Leucine Rich Repeat Kinase 2 (LRRK2). Autosomal dominant mutations in LRRK2 cause familial PD, while mutations in LRRK2 are risk factors for sporadic PD and increased activity of LRRK2’s kinase has been linked to the sporadic form of the disease as well. This has made LRRK2 the main actionable target for PD therapeutics.


